EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe V. Wade Overturn, CEO Says
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe V. Wade Overturn, CEO Says
獨家報道：Femasys處於拐點之上，被低估，預計在羅訴韋德案推翻後有增長潛力，CEO表示
Femasys Inc (NASDAQ:FEMY) is a biomedical company focused on women's healthcare.
Femasys Inc（納斯達克：FEMY）是一家專注於婦女保健的生物醫藥公司。
The company, with a market capitalization of $22.50 million as of data from Benzinga Pro on 17 June, went public in June 2021.
該公司市值爲2250萬美元，截至6月17日的Benzinga Pro數據，於2021年6月上市。
In an emailed interview with Benzinga, Kathy Lee-Sepsick, the founder & CEO of Femasys, said, "I considered permanent birth control but found the available options too risky."
Femasys的創始人兼首席執行官Kathy Lee-Sepsick在一份發給Benzinga的電子郵件採訪中表示：“我曾考慮過永久避孕，但發現現有的選擇太冒險了。”
Femasys' commercially available products are:
Femasys的商業化產品包括：
FemaSeed: A form of artificial insemination where sperm is delivered directly and safely into the fallopian tube
FemVue: A contrast-generating device for ultrasound evaluation.
FemCath: A delivery catheter for fallopian tube and uterine...
FemaSeed：一種通過直接安全地將精子引入輸卵管的人工授精方式
...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。